Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director · CHIEF EXECUTIVE OFFICER | September 29, 2025 | October 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date September 29, 2025 · Filed October 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2035-09-28 | Direct | 1,875,000 |
Reported balance
After 2025-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-29 · Grant · Acquired 1,875,000 · Balance 1,875,000 F1: This stock option becomes exercisable in 48 monthly installments beginning on September 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable in 48 monthly installments beginning on September 29, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2025 Filed Oct 3, 2025 00:13 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 1,875,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001193125-25-228920 · ownership.xml · derivative · entry 1 Azam Usman · CIK 0002089768 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875,000 Underlying: Common Stock · 1,875,000 shares Expires 2035-09-28 F1 · derivative.exercise_date: This stock option becomes exercisable in 48 monthly installments beginning on September 29, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.